Company: APXIF
Filing Date: 2025-07-03
Form Type: F-4/A
Source: 0001213900-25-061545
Chunk: 390

Company: APx Acquisition Corp. I
Filing Date: 2025-07-03
Form: F-4/A
Chunk 390
---
 accuracy of a genetic diagnostic test. By applying the highest international standards in our clinical studies, we strive to ensure that we can use the information irrespective of borders. If necessary, we gather local data to validate genomic backgrounds and environmental conditions. Cardiovascular Disease Polygenic Risk Score (PRS) Study A cross -sectionalstudy was conducted from June 2022 to October 2023, sponsored by our subsidiary, Heritas Argentina and in collaboration with Hospital Italiano de Rosario. Principal Investigator (P.I.): M.D. Anibal Gentiletti. Approved by the hospital’s ethics committee, the study involved 155 participants aged 30 -85, divided into cases and controls: •Cases (n=39): Individuals with a CAD diagnosis. •Controls (n=111): Individuals without a CAD diagnosis, family history, or associated clinical risk factors. Each participant’s genetic material was purified from a saliva sample and analyzed using low -coveragewhole -genomesequencing with our imputation platform, calculating the PRS from approximately 1.7 million markers. Results showed a statistically significant difference between cases and controls (p -value: 0.000288), with higher PRS values associated with increased risk. The area under the curve (AUC) was 0.767, indicating moderate -to -highpredictive capacity Breast Cancer PRS Study Another cross -sectionalstudy, conducted from September 2021 to October 2023, was sponsored by Heritas Argentina in collaboration with Centro de Mastología Rosario. P.I.: M.D. Gonzalo Tabares. Approved by Comité de Etica Caici -Ciap, Rosario, Argentina, the study included female participants aged 45 – 65: •Cases (n=140): Women with a breast cancer diagnosis before age45, negative for high/moderate -penetrancegenes, and a family history of breast cancer. •Controls (n=91): Women without a breast cancer diagnosis or family history of breast cancer. Genetic material from blood or saliva samples underwent low -coveragewhole -genomesequencing, with PRS calculations based on 77 markers. Mean PRS values were statistically significantly different between cases and controls (p -value: 1.54e -5). The AUC was 0.62, showing moderate predictive capacity for breast cancer risk. 196 In both studies, participant data, including health and lifestyle information, were anonymized and coded. These findings demonstrate the PRS